Extended lymphadenectomy at the time of radical cystectomy did not produce a significant improvement in disease-free survival (DFS) or overall survival (OS) vs standard lymphadenectomy for patients with muscle-invasive bladder cancer.
The FDA has issued a complete response letter regarding the biologics license application for N-803 in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease.
The FDA has granted 510K clearance to Bladder EpiCheck for use as a noninvasive method for surveillance of tumor recurrence in previously diagnosed patients with non–muscle invasive bladder cancer, in conjunction with cystoscopy.
Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.